Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;9(2):172-179.
doi: 10.21037/tlcr.2020.03.10.

Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future

Kazushige Wakuda  1
Affiliations
Editorial

Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future

Kazushige Wakuda. Transl Lung Cancer Res. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2020.03.10). KW reports personal fees from Chugai Pharmaceutical Co, Ltd., personal fees from Ono Pharmaceutical Co, Ltd., personal fees from Boeringer Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Taiho Pharma, personal fees from AstraZeneca K.K., outside the submitted work.

Comment on

References

    1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44. 10.1200/JCO.2005.04.4859 - DOI - PubMed
    1. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7. 10.1200/JCO.2006.06.5821 - DOI - PubMed
    1. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-6. 10.1200/JCO.2008.18.1974 - DOI - PubMed
    1. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-53. 10.1200/JCO.2006.08.4145 - DOI - PubMed
    1. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014;32:4012-9. 10.1200/JCO.2013.54.5392 - DOI - PubMed